Protara Therapeutics is a biopharmaceutical company that focuses on identifying and advancing transformative therapies for treating cancer and rare diseases. Their lead program is TARA-002, a cell therapy developed to treat lymphatic malformations. They also develop investigational phospholipid substrate replacement therapy to treat intestinal failure-associated liver disease.